General Information of Drug (ID: DM1QPG7)

Drug Name
LVVYPWT Drug Info
Synonyms
Spinorphin; 137201-62-8; LVVYPWT; Leu-val-val-tyr-pro-trp-thr; CHEMBL395493; L-Threonine, N-(N-(1-(N-(N-(N-L-leucyl-L-valyl)-L-valyl)-L-tyrosyl)-L-prolyl)-L-tryptophyl)-; (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid; LVV-hemorphin-4; AC1MIXNC; SPINORPHIN, BOVINE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3081832
CAS Number
CAS 137201-62-8
TTD Drug ID
DM1QPG7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting P2X purinoceptor 3 (P2RX3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefapixant DM4GWL7 Cough MD12 Phase 3 [3]
BAY-1902607 DMYSQMW Cough MD12 Phase 2 [3]
BAY 1902607 DMFA4CK Cough MD12 Phase 1/2 [3]
AF-130 DM8LG2I Hypertension BA00-BA04 Phase 1 [4]
BAY-1817080 DMNL5G7 Endometriosis GA10 Phase 1 [3]
BAY 1817080 DMF9ALP Cough MD12 Phase 1 [5]
BzATP DM37GYA Discovery agent N.A. Investigative [6]
TNP-ATP DMVZY0X Discovery agent N.A. Investigative [7]
ISOPPADS DMWI0M8 Discovery agent N.A. Investigative [8]
LVAYPWT DMIO405 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 3 (P2RX3) TT2THBD P2RX3_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1026).
2 Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
7 Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
8 Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.